First Tracks to Report Phase 1b Celiac Data for ANB033 on Oct. 12
First Tracks Biotherapeutics plans to release top-line results from Cohort 1 of a global Phase 1b study of ANB033 in celiac disease on October 12, 2026. The trial uses a gluten challenge to assess whether the CD122 antagonist can prevent mucosal damage. The company will issue a morning press release and discuss the findings during an 8:30 a.m. ET webcast, with a replay available for at least 30 days.
First Tracks Biotherapeutics, trading as TRAX, is a clinical-stage company developing antibody treatments that influence immune pathways tied to autoimmune and inflammatory conditions. Its pipeline includes ANB033 for celiac disease and eosinophilic esophagitis, rosnilimab for rheumatoid arthritis, and ANB101, a BDCA2 modulator.
On Oct. 12, 2026, the company plans to disclose initial results from Cohort 1 of a worldwide Phase 1b study of ANB033, a CD122 antagonist. That cohort uses gluten exposure to test whether the drug can stop intestinal lining injury. A morning release will precede an 8:30 a.m. ET investor webcast, with replay access for at least 30 days.
The readout may matter most to people with celiac disease and their clinicians, who could gain early insight into whether a new immune-targeting approach might someday supplement or reduce reliance on strict gluten avoidance. Investors and biotech watchers may see the event as a near-term signal for TRAX, while any societal effect would depend on later-stage safety, efficacy, and access.